CGEM Cullinan Oncology Inc

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management team will participate in two upcoming investor conferences and will host a company event at the 2025 American Society of Hematology (“ASH”) Annual Meeting in Orlando, FL.

  • Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York, NY on Tuesday, November 11, 2025, at 3:20 p.m. ET.



  • Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 8:00 a.m. ET.



  • The Company will host an in-person event for analysts and institutional investors on Monday, December 8, at 8:00 p.m. ET, during the 2025 ASH Annual Meeting. The event will follow the oral presentation of results from the Phase 1 study of CLN-049 in patients with AML or MDS earlier that morning (Presentation ID 768). Investors and analysts are invited to register to attend in person by emailing Nick Smith, Head of Investor Relations ().



Webcasts of the fireside chats and the ASH event will be available under the Events and Presentations section of the Company’s investor relations website at .

About Cullinan Therapeutics

 (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at , and follow us on  and .

Contacts:

Investor Relations

Nick Smith

+1 401.241.3516

Media

Rose Weldon

+1 215.801.7644



EN
10/11/2025

Underlying

CGEMCullinan Oncology Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cullinan Oncology Inc

David Nierengarten ... (+9)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
KURA KURA ONCOLOGY INC.
FATE FATE THERAPEUTICS INC
WVE WAVE LIFE SCIENCES
DNLI DENALI THERAPEUTICS INC
ORIC ORIC PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
RZLT REZOLUTE
CGEM CULLINAN ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
12/02/25 December 2, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049,...

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S...

December 1, 2025 1 EN
Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
CGEM CULLINAN ONCOLOGY INC
11/20/25 November 20, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Participate in Upcoming Investor Conferences ...

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management team will participate in two upcoming investor conferences and will host a company event at the 2025 American Society of Hematology (“ASH”) Annual Meeting in Orlando, FL. Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A.,...

November 10, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Provides Corporate Update and Reports Third Quar...

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to be presented in oral presentation at ASH 2025 Company to share initial data for CLN-978, a CD19xCD3 bispecific T cell engager, in both SLE and RA in first half of 2026 Based on review of emerging clinical data, CLN-619 and CLN-617 programs discontinued Cash and investments of $475.5 million ...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch